《新股表現》康諾亞生物(02162.HK)暗盤高開8.8%報58元
根據輝立交易平台顯示,明天掛牌的康諾亞生物-B(02162.HK)暗盤高開8.8%報58元,高低暫見69.5元/57元,現造68.7元,較上市價53.3元,高近29%,成交209萬股。
康諾亞是一家生物科技公司,擁有五種臨床階段的候選藥物,在國產同靶點藥物或同類別藥物中,每種均處於取得中國或美國臨床試驗申請批准前三位。公司主要專注於自主發現及開發自體免疫及腫瘤治療領域的創新生物療法。核心產品CM310,用於治療多種過敏性疾病,如中重度特應性皮炎(AD)、中重度嗜酸性哮喘和慢性鼻竇炎伴鼻息肉(CRSwNP)及潛在慢性阻塞性肺疾病(COPD)。
康諾亞是次上市共發售5,826.45萬股,並已引入包括Invesco、UBS、Temasek、Hillhouse Capital及Boyu Capital Opportunities Master Fund等15名基石投資者,合共認購2,767.15萬股;10%公開發售獲近429倍超購,已啟動回撥機制佔比增至50%,認購一手中籤率僅6.5%;股份以招股範圍(50.5-53.3)上限定價,料集資淨額約29.42億元,主要用作核心與主要產品研發和商業化、用於其他在研產品臨床前評估和臨床開發、公司新生產及研發設施租賃付款等。上市聯席保薦人分別為大摩、中金及華泰國際。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.